Brooks Laboratories Ltd (BROOKS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 533543 | NSE: BROOKS | Pharmaceuticals & Drugs | Small Cap

Brooks Laboratories Share Price

100 0.30 0.30%
as on 05-Dec'25 12:17

Brooks Laboratories Ltd (BROOKS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 533543 | NSE: BROOKS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Brooks Laboratories

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Brooks Laboratories stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
42.05
Market Cap:
293.7 Cr.
52-wk low:
96
52-wk high:
202.8

Is Brooks Laboratories Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Brooks Laboratories: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Brooks Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 9.7%2.6%-10.6%-8.6%-7.8%-5.2%1.9%-11.2%3.5%4.4%-
Value Creation
Index
-0.3-0.8-1.8-1.6-1.6-1.4-0.9-1.8-0.8-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 8057.555.75569.777.37755.579.582.6111
Sales YoY Gr.--28.1%-3.2%-1.2%26.6%10.9%-0.4%-27.8%43.1%3.9%-
Adj EPS 5.40.9-7.1-7.7-9.4-6.30.1-3.30.512.4
YoY Gr.--84.3%-929.4%NANANANA-2435.7%NA85.2%-
BVPS (₹) 62.365.458.450.839.525.726.122.826.539.140.7
Adj Net
Profit
10.61.7-13.8-15.1-23.4-15.70.3-8.21.42.97
Cash Flow from Ops. 8.19.6-6.2-5.1-9.4-0.93.10.6-9.82.6-
Debt/CF from Ops. 0.71.4-4.5-6.2-2.9-9.31.610.3-0.52.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.4%3.5%2.4%3.9%
Adj EPS -17.1%NA92.6%85.2%
BVPS-5.1%-0.2%14.4%47.5%
Share Price 2.9% 8% -5.6% -26.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
9.11.3-11.4-13.7-23-19.30.5-13.42.23.25.9
Op. Profit
Mgn %
13.98.8-16-15.2-3.71.32.4-10.43.91.78.2
Net Profit
Mgn %
13.22.9-24.8-27.4-33.6-20.30.4-14.71.83.66.3
Debt to
Equity
0.10.10.20.30.30.10.10.10.10.10
Working Cap
Days
21622720823420616815922614415069
Cash Conv.
Cycle
2527-77343129195226

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Brooks Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 2.4 3.9
TTM Sales (₹ Cr.) 111 111
BVPS (₹.) 40.7 39.3
Reserves (₹ Cr.) 91 86
P/BV 2.45 2.54
PE 42.05 25.47
From the Market
52 Week Low / High (₹) 95.95 / 202.80
All Time Low / High (₹) 10.32 / 202.80
Market Cap (₹ Cr.) 294
Equity (₹ Cr.) 29.5
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Brooks Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Brooks Laboratories - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Brooks Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales80585655707777567983
Operating Expenses 69526563747675617681
Manufacturing Costs4386787456
Material Costs53373939474849405754
Employee Cost 561010111211111012
Other Costs 7688998659
Operating Profit 115-9-8-412-631
Operating Profit Margin (%) 13.9%8.8%-16.0%-15.2%-5.6%1.2%2.4%-10.5%3.9%1.7%
Other Income 2003011014
Interest 1123331111
Depreciation 1266771222
Exceptional Items 0000000000
Profit Before Tax 112-18-15-14-81-823
Tax 01-4-01170000
Profit After Tax 112-14-15-24-161-823
PAT Margin (%) 13.3%2.9%-24.8%-26.9%-35.0%-20.2%0.9%-14.7%1.9%3.7%
Adjusted EPS (₹)5.40.9-7.1-7.6-9.8-6.30.3-3.30.61.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 1221281141009864655770115
Share Capital 16161616252525252629
Reserves 1061129883744040324386
Minority Interest0000000000
Debt61325282485656
Long Term Debt01117141110000
Short Term Debt529141375656
Trade Payables16182727261326231514
Others Liabilities 13-2-42978746
Total Liabilities 156158162157158931039294141

Fixed Assets

Gross Block231271321321332021232325
Accumulated Depreciation72815195681011
Net Fixed Assets 161251241171131515151414
CWIP 87010001000
Investments 011004747474791
Inventories78111014121711109
Trade Receivables19111011161015131620
Cash Equivalents 2223211111
Others Assets 251213141488576
Total Assets 156158162157158931039294141

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 810-6-5-9-131-103
PBT 112-18-15-14-81-823
Adjustment 1310912102321
Changes in Working Capital 2621-8206-13-3
Tax Paid -5-2-1-1-0-4-0-001
Cash Flow From Investing Activity -14-17-51-2-11-00-45
Capex -34-17-61-2-11-0-0-1
Net Investments 20000-00-0-01-44
Others 1000000000
Cash Flow From Financing Activity 47126101-4-01042
Net Proceeds from Shares 000000001143
Net Proceeds from Borrowing 0000000000
Interest Paid -1-1-3-3-3-3-1-1-1-1
Dividend Paid 0000000000
Others 58149134-41-11
Net Cash Flow -1-012-2-00-00-0

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)9.111.33-11.38-13.83-24.62-19.171.03-13.442.423.31
ROCE (%)9.692.59-10.64-8.6-7.77-5.241.87-11.213.54.35
Asset Turnover Ratio0.550.410.360.350.440.620.780.570.850.7
PAT to CFO Conversion(x)0.735N/AN/AN/AN/A3N/A-51
Working Capital Days
Receivable Days87836772715958916780
Inventory Days32406171626269924842
Payable Days12017020924920715114522212598

Brooks Laboratories Ltd Stock News

Brooks Laboratories Ltd FAQs

The current trading price of Brooks Laboratories on 05-Dec-2025 12:17 is ₹100.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Brooks Laboratories stood at ₹293.7.
The latest P/E ratio of Brooks Laboratories as of 04-Dec-2025 is 42.05.
The latest P/B ratio of Brooks Laboratories as of 04-Dec-2025 is 2.45.
The 52-week high of Brooks Laboratories is ₹202.8 and the 52-week low is ₹95.95.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Brooks Laboratories is ₹110.7 ( Cr.) .

About Brooks Laboratories Ltd

The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production.

The company has set up a well equipped manufacturing unit at Baddi, Himachal Pradesh in the year 2006 and has been awarded a G.M.P Certification for following Good Manufacturing Practices under “Revised Schedule M” of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, Capsules, Liquid Orals, Dry Syrups, SVP (Liquid & Dry) and Ophthalmic Section by The Health & Family Welfare Department, Himachal.

Company’s manufacturing facility at Baddi is capable of manufacturing products confirming to TRS 908 of 2003 (WHO GMP) standards. Its Quality Management System at the factory at Baddi is certified as complying to ISO 9001:2008.

Product of the company

The company has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials. These products are manufactured in accordance with highest international standards in facilities as per norms of WHO-GMP & ISO 9000-2008.

Some of the product categories are:

  • Beta Lactum
  • Cephalosporins
  • Carbapenems
  • General Injectable (Dry Powder)
  • General Injectable (Liquid)
  • Cortico Steroids
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×